Lifesciences@Work : We help scientists build their business

Mucosis

Mucosis B.V. is a Dutch biotechnology company with a proprietary platform technology, Mimopath™, on which it develops mucosal vaccines with improved efficacy.

Mucosis’ lead products are FluGEM™, a vaccine to prevent influenza; PneuGEM™, a vaccine to prevent diseases caused by pneumococcal bacteria; and SynGEM™, a vaccine to prevent RSV viral infection.

Mimopath™-based vaccines can be administered needle-free in the nose and mouth, evoking a more natural immune response with a broader base of protection.